Summary & Overview
HCPCS Level II Q9981: Rolapitant, Oral, 1 mg
HCPCS Level II code Q9981 denotes rolapitant, an oral neurokinin-1 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting. As an HCPCS Level II drug code, Q9981 is used on medical claims to identify the specific drug formulation and unit dose for billing and pharmacy reimbursement. Nationally, accurate reporting of this code supports appropriate drug utilization tracking, payment adjudication, and clinical quality measurement in oncology supportive care.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for rolapitant, common sites of service where oral antiemetic therapy is provided, and what to expect in claims reporting when using Q9981 on medical service lines. The publication also outlines typical benchmarks and policy considerations relevant to drug coding and billing, highlights potential payer coverage variability, and summarizes common administrative issues to watch for when documenting oral oncology supportive medications.
This resource is intended for billing professionals, revenue cycle staff, and clinical administrators seeking a national-level reference for reporting and understanding the use of HCPCS Level II code Q9981.
Billing Code Overview
HCPCS Level II code Q9981 represents Rolapitant, oral, 1 mg. This billing code is used to report the administration or dispensing of the oral antiemetic medication rolapitant in a 1 mg unit form. Service type: outpatient oral medication/antiemetic therapy. Typical site of service: outpatient settings such as physician offices, oncology infusion centers with take-home or oral supportive-care dispensation, and ambulatory clinics.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving Q9981 (rolapitant, oral, 1 mg) is an adult oncology patient undergoing moderately to highly emetogenic chemotherapy who requires additional antiemetic prophylaxis to prevent delayed chemotherapy-induced nausea and vomiting (CINV). The patient presents to an outpatient oncology infusion center for scheduled chemotherapy. During pre-treatment assessment the oncology clinician documents prior CINV history, current antiemetic regimen, concomitant medications, and hepatic/renal function. The clinician prescribes oral Q9981 to be administered per protocol (commonly the day of chemotherapy) as part of a multi-agent antiemetic regimen that may include a 5-HT3 receptor antagonist (e.g., ondansetron), dexamethasone, and other supportive agents.
In the clinical workflow, the order for Q9981 is entered into the electronic health record; the medication is verified by pharmacy for dose and interactions (notably CYP interactions), dispensed or given per clinic protocol, and documented in the medication administration record. Nursing confirms patient identity, documents administration or dispensing, and provides patient education about possible adverse effects and follow-up instructions for nausea control. Billing uses the HCPCS Level II code Q9981 to report the oral rolapitant product.
Coding Specifications
| Modifier | Description | When to Use |
|---|